CN113640416A - Content determination method of levofloxacin hydrochloride tablets - Google Patents
Content determination method of levofloxacin hydrochloride tablets Download PDFInfo
- Publication number
- CN113640416A CN113640416A CN202110923461.6A CN202110923461A CN113640416A CN 113640416 A CN113640416 A CN 113640416A CN 202110923461 A CN202110923461 A CN 202110923461A CN 113640416 A CN113640416 A CN 113640416A
- Authority
- CN
- China
- Prior art keywords
- levofloxacin hydrochloride
- hydrochloride tablets
- levofloxacin
- content
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000001514 detection method Methods 0.000 claims abstract description 20
- QWSZRRAAFHGKCH-UHFFFAOYSA-M sodium;hexane-1-sulfonate Chemical compound [Na+].CCCCCCS([O-])(=O)=O QWSZRRAAFHGKCH-UHFFFAOYSA-M 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 14
- 229960003376 levofloxacin Drugs 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 239000012085 test solution Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 5
- 239000011550 stock solution Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 238000010812 external standard method Methods 0.000 claims description 3
- 239000012488 sample solution Substances 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 8
- 238000000926 separation method Methods 0.000 abstract description 3
- 239000000706 filtrate Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 241001397104 Dima Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
- G01N30/8634—Peak quality criteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Quality & Reliability (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a content detection method of levofloxacin hydrochloride tablets, which adopts high performance liquid chromatography for detection, and the mobile phase is a mixture of the following components in volume ratio (1.5-2.0): 1 sodium hexane sulfonate solution and methanol. The invention provides a content detection method of levofloxacin hydrochloride tablets, which adopts sodium hexane sulfonate solution and methanol with a specific volume ratio as mobile phases and can effectively shorten retention time on the premise of ensuring that the chromatogram of the levofloxacin hydrochloride tablets has good peak shape and the separation degree and the theoretical plate number accord with the specification, thereby reducing the consumption of the mobile phases and improving the detection efficiency.
Description
Technical Field
The invention relates to the field of medicine quality control, in particular to a content detection method of levofloxacin hydrochloride tablets.
Background
Levofloxacin is a novel fluoroquinolone drug developed by first pharmaceutical corporation of japan in 1986, is an optically active L-isomer of ofloxacin, and is first marketed in japan at the end of 1993. Compared with the levofloxacin, the hydrochloride (levofloxacin hydrochloride) of the levofloxacin hydrochloride is relatively stable, has long storage time, relatively simple pharmaceutical process and easier absorption, and the medicament can quickly and widely permeate into various tissues and body fluids of a body. Can be used for treating infection caused by sensitive Staphylococcus, pneumococcus, Streptococcus pyogenes, hemolytic streptococcus, enterococcus, peptic streptococcus, gonococcus, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, and Chlamydia trachomatis. The levofloxacin is completely absorbed by oral administration, so that the levofloxacin is beneficial to preparing an oral preparation which is convenient to use, and the medicines circulating in the market at present mainly comprise tablets and hard capsules.
The 2000 edition of Chinese pharmacopoeia (2004. supplement) adopts high performance liquid chromatography to measure the content of levofloxacin hydrochloride tablets, and adopts sodium hexane sulfonate solution-methanol (3:1) as a mobile phase. However, this method causes the retention time of levofloxacin hydrochloride and its main impurities to be too long, adversely affecting the working efficiency and increasing the consumption of mobile phase.
Therefore, under the condition of ensuring the accurate content measurement of the levofloxacin hydrochloride tablets, the retention time of the chromatogram is reduced as much as possible, and the method is very favorable for quality control in large-scale production of factories.
Disclosure of Invention
In view of this, the present invention provides a method for detecting the content of levofloxacin hydrochloride tablets, so as to reduce the retention time of chromatography.
The specific technical scheme is as follows:
the invention provides a content detection method of levofloxacin hydrochloride tablets, which adopts high performance liquid chromatography for detection, and the mobile phase is a mixture of the following components in volume ratio of (1.5-2.0): 1 sodium hexane sulfonate solution and methanol.
In some embodiments of the invention, the mobile phase is a mixture of 1.8:1 sodium hexane sulfonate solution and methanol.
In some embodiments of the invention, the chromatographic conditions comprise:
a chromatographic column: octadecylsilane chemically bonded silica;
the column temperature is 40 ℃;
the detection wavelength was 293 nm.
In some embodiments of the invention, the method comprises the steps of:
(1) dissolving levofloxacin hydrochloride tablets in a hydrochloric acid aqueous solution to obtain a sample stock solution;
(2) diluting the sample stock solution with the hydrochloric acid aqueous solution to obtain a sample test solution;
(3) injecting the test solution into a liquid chromatograph, recording the chromatogram, and reading the peak area S of levofloxacin hydrochlorideFor supplying to；
(4) According to the steps (1) to (3), measuring the levofloxacin contrast product by the same method, recording the chromatogram, and reading the peak area S of the levofloxacinTo pair；
(5) According to SFor supplying toAnd STo pairAnd determining the content of the levofloxacin hydrochloride tablets according to an external standard method.
In some embodiments of the invention, the concentration of the test solution is in the range of 0.06 to 0.14 mg/ml.
In some embodiments of the invention, the concentration of the test solution is in the range of 0.1 mg/ml.
In some embodiments of the invention, the concentration of the aqueous hydrochloric acid solution in steps (1) to (2) is 0.03 mol/ml.
Advantageous effects
The invention provides a content detection method of levofloxacin hydrochloride tablets, which adopts sodium hexane sulfonate solution and methanol with a specific volume ratio as mobile phases and can effectively shorten retention time on the premise of ensuring that the chromatogram of the levofloxacin hydrochloride tablets has good peak shape and the separation degree and the theoretical plate number accord with the specification, thereby reducing the consumption of the mobile phases and improving the detection efficiency.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more apparent, the technical solutions of the present application will be clearly and completely described below through specific embodiments.
In the following examples, those not indicated with specific conditions were performed according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
EXAMPLE 1 determination of the Mobile phase
The flow phase levofloxacin hydrochloride tablets of table 1 below were used for the detection, respectively.
TABLE 1
| Mobile phase 1 | Sodium hexane sulfonate solution-methanol (3:1) |
| Mobile phase 2 | Sodium hexane sulfonate solution-methanol (1.8:1) |
| Mobile phase 3 | Sodium hexane sulfonate solution-methanol (1.5:1) |
Wherein, the sodium hexane sulfonate solution is prepared as follows:
0.98g of sodium hexane sulfonate is taken and added with phosphate buffer (6.8 g of monopotassium phosphate is taken and dissolved by water and diluted to 1000ml, about 500ml of 0.05mol/L phosphoric acid is added, and the pH value is adjusted to 2.4.
The chromatographic conditions were as follows:
stationary phase: dima C18 column, 4.6X 200mm, 5um,
mobile phase: see Table 1
Flow rate: 1.0ml/min of the mixture is added,
detection wavelength: the wavelength of the light beam is 293nm,
column temperature: at a temperature of 40 c,
sample introduction amount: 20 μ l.
The detection steps are as follows:
(1) placing levofloxacin hydrochloride tablets (about equivalent to 50mg of levofloxacin) into a 50ml measuring flask, adding 0.03mol/ml hydrochloric acid solution to dissolve and dilute to scale, shaking up, and filtering;
(2) precisely measuring 5ml of the subsequent filtrate, placing the subsequent filtrate in a 50ml measuring flask, adding a mobile phase to dilute the subsequent filtrate to a scale, and shaking up to obtain a sample test solution;
(3) and (4) injecting 20 mu l of the test solution into a liquid chromatograph, and recording the chromatogram.
By adopting the mobile phase, the levofloxacin hydrochloride tablets have good peak shapes, the retention time of the main peak is relatively short when the ratio of the mobile phase 3 is (1.5:1), the retention time of the main peak is longer when the ratio of the mobile phase 1 (the mobile phase recorded in Chinese pharmacopoeia) is (3:1), the retention time of the mobile phase is about 10 minutes when the ratio of the mobile phase is (1.8:1) and the flow rate is 1.0ml/min, and the separation degree and the number of theoretical plates are both in accordance with the specification. Therefore, to reduce the consumption of the mobile phase, providing detection efficiency, the mobile phase according to the present invention is a mobile phase having a volume ratio of (1.5-2.0): 1-methanol, mobile phase 2 (1.8:1) is preferably used as the content determination mobile phase for levofloxacin hydrochloride tablets according to the invention.
EXAMPLE 2 determination of the Linear Range of the assay
Weighing appropriate amount of levofloxacin reference, precisely weighing, adding mobile phase for dissolving, and quantitatively diluting to obtain a stock solution containing levofloxacin reference 0.2 mg/ml; precisely measuring 3ml, 4ml, 5ml, 6ml and 7ml, respectively placing into 10ml measuring flask, adding mobile phase to dilute to scale, shaking, precisely measuring 20 μ l of sample solution, injecting into liquid chromatograph, recording chromatogram, and referring to example 1 (mobile phase selected mobile phase 2). The test results are given in the following table: the results are shown in Table 1 below:
TABLE 1 measurement results of the Linear relationship test
The regression analysis confirms that the sample injection concentration is in a good linear relation within the range of 0.06mg/ml to 0.14mg/ml, and can meet the requirement of content determination.
Example 3 content measurement of levofloxacin hydrochloride tablets
The content of the self-made levofloxacin hydrochloride tablets of 3 batches is detected by adopting the high performance liquid chromatography detection method provided by the invention.
The chromatographic conditions were as follows:
stationary phase: dima C18 column, 4.6X 200mm, 5um,
mobile phase: sodium hexane sulfonate solution-methanol (1.8:1),
flow rate: 1.0ml/min of the mixture is added,
detection wavelength: the wavelength of the light beam is 293nm,
column temperature: at a temperature of 40 c,
sample introduction amount: 20 μ l.
The detection steps are as follows:
(1) placing levofloxacin hydrochloride tablets (about equivalent to 50mg of levofloxacin) into a 50ml measuring flask, adding 0.03mol/ml hydrochloric acid solution to dissolve and dilute to scale, shaking up, and filtering;
(2) precisely measuring 5ml of the subsequent filtrate, placing the subsequent filtrate in a 50ml measuring flask, adding a mobile phase to dilute the subsequent filtrate to a scale, and shaking up to obtain a sample test solution;
(3) injecting 20 μ l of the sample solution into a liquid chromatograph, recording chromatogram, and reading the peak area S of levofloxacin hydrochlorideFor supplying to；
(4) Taking levofloxacin reference (130455-To pair；
(5) According to SFor supplying toAnd STo pairThe content of levofloxacin hydrochloride tablets was determined by external standard method, and the results are shown in table 2 below.
TABLE 2 results of content measurement
Note: the contents in table 2 refer to contents in relative amounts.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (7)
1. A content detection method of levofloxacin hydrochloride tablets adopts high performance liquid chromatography for detection, and is characterized in that a mobile phase is a mixture of levofloxacin hydrochloride tablets and levofloxacin hydrochloride tablets in a volume ratio of (1.5-2.0): 1 sodium hexane sulfonate solution and methanol.
2. The method for detecting the content of levofloxacin hydrochloride tablets according to claim 1, wherein the mobile phase is a mixture of the mobile phase and the levofloxacin hydrochloride tablet at a volume ratio of 1.8:1 sodium hexane sulfonate solution and methanol.
3. The method for detecting the content of levofloxacin hydrochloride tablets according to claim 1, wherein the chromatographic conditions comprise:
a chromatographic column: octadecylsilane chemically bonded silica;
the column temperature is 40 ℃;
the detection wavelength was 293 nm.
4. The method for detecting the content of levofloxacin hydrochloride tablets according to claim 1, wherein the method comprises the following steps:
(1) dissolving levofloxacin hydrochloride tablets in a hydrochloric acid aqueous solution to obtain a sample stock solution;
(2) diluting the sample stock solution with the hydrochloric acid aqueous solution to obtain a sample test solution;
(3) injecting the sample solution into liquid chromatograph, and recording chromatogramDrawing, and reading the peak area S of levofloxacin hydrochlorideFor supplying to；
(4) According to the steps (1) to (3), measuring the levofloxacin contrast product by the same method, recording the chromatogram, and reading the peak area S of the levofloxacinTo pair；
(5) According to SFor supplying toAnd STo pairAnd determining the content of the levofloxacin hydrochloride tablets according to an external standard method.
5. The method for detecting the content of levofloxacin hydrochloride tablets according to claim 1, wherein the concentration of the test solution is in the range of 0.06-0.14 mg/ml.
6. The method for detecting the content of levofloxacin hydrochloride tablets according to claim 5, wherein the concentration of the test solution is in the range of 0.1 mg/ml.
7. The method for detecting the content of levofloxacin hydrochloride tablets according to claim 4, wherein the concentration of the aqueous hydrochloric acid solution in the steps (1) to (2) is 0.03 mol/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110923461.6A CN113640416A (en) | 2021-08-12 | 2021-08-12 | Content determination method of levofloxacin hydrochloride tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110923461.6A CN113640416A (en) | 2021-08-12 | 2021-08-12 | Content determination method of levofloxacin hydrochloride tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113640416A true CN113640416A (en) | 2021-11-12 |
Family
ID=78421054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110923461.6A Pending CN113640416A (en) | 2021-08-12 | 2021-08-12 | Content determination method of levofloxacin hydrochloride tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113640416A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102342910A (en) * | 2011-10-03 | 2012-02-08 | 白求恩医科大学制药厂 | Levofloxacin hydrochloride injection pharmaceutical composition and preparation method thereof |
| US20120157492A1 (en) * | 2008-07-15 | 2012-06-21 | Taigen Biotechnology Co., Ltd. | Antibiotic drug |
| AU2013203952A1 (en) * | 2005-10-05 | 2013-05-02 | Otsuka Pharmaceutical Co., Ltd. | Antituberculous composition comprising oxazole compounds |
| US20140329739A1 (en) * | 2011-04-18 | 2014-11-06 | Jiangsu Protelight Pharmaceutical & Biotechnology Co., Ltd. | Antibiotic peptide and preparation method therefor and application therefor |
| CN105687157A (en) * | 2014-11-29 | 2016-06-22 | 康普药业股份有限公司 | Levofloxacin hydrochloride capsule and preparation method thereof |
| CN106769963A (en) * | 2016-12-08 | 2017-05-31 | 湖北远大天天明制药有限公司 | A kind of method for separating and/or detecting lavo-ofloxacin and methyl hydroxybenzoate in lavo-ofloxacin hydrochloride gel for eye |
| CN109580837A (en) * | 2018-12-31 | 2019-04-05 | 辰欣药业股份有限公司 | A kind of detection method of Levofloxacin Hydrochloride Injection |
| CN111458436A (en) * | 2020-04-18 | 2020-07-28 | 山东齐都药业有限公司 | Method for measuring photodegradation impurities in levofloxacin raw material and preparation |
| CN111855840A (en) * | 2020-06-30 | 2020-10-30 | 辰欣药业股份有限公司 | Method for detecting related substances in levofloxacin hydrochloride injection |
| CN112569229A (en) * | 2019-09-29 | 2021-03-30 | 扬子江药业集团南京海陵药业有限公司 | Preparation containing ornidazole compound and preparation method and application thereof |
-
2021
- 2021-08-12 CN CN202110923461.6A patent/CN113640416A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203952A1 (en) * | 2005-10-05 | 2013-05-02 | Otsuka Pharmaceutical Co., Ltd. | Antituberculous composition comprising oxazole compounds |
| US20120157492A1 (en) * | 2008-07-15 | 2012-06-21 | Taigen Biotechnology Co., Ltd. | Antibiotic drug |
| US20140329739A1 (en) * | 2011-04-18 | 2014-11-06 | Jiangsu Protelight Pharmaceutical & Biotechnology Co., Ltd. | Antibiotic peptide and preparation method therefor and application therefor |
| CN102342910A (en) * | 2011-10-03 | 2012-02-08 | 白求恩医科大学制药厂 | Levofloxacin hydrochloride injection pharmaceutical composition and preparation method thereof |
| CN105687157A (en) * | 2014-11-29 | 2016-06-22 | 康普药业股份有限公司 | Levofloxacin hydrochloride capsule and preparation method thereof |
| CN106769963A (en) * | 2016-12-08 | 2017-05-31 | 湖北远大天天明制药有限公司 | A kind of method for separating and/or detecting lavo-ofloxacin and methyl hydroxybenzoate in lavo-ofloxacin hydrochloride gel for eye |
| CN109580837A (en) * | 2018-12-31 | 2019-04-05 | 辰欣药业股份有限公司 | A kind of detection method of Levofloxacin Hydrochloride Injection |
| CN112569229A (en) * | 2019-09-29 | 2021-03-30 | 扬子江药业集团南京海陵药业有限公司 | Preparation containing ornidazole compound and preparation method and application thereof |
| CN111458436A (en) * | 2020-04-18 | 2020-07-28 | 山东齐都药业有限公司 | Method for measuring photodegradation impurities in levofloxacin raw material and preparation |
| CN111855840A (en) * | 2020-06-30 | 2020-10-30 | 辰欣药业股份有限公司 | Method for detecting related substances in levofloxacin hydrochloride injection |
Non-Patent Citations (2)
| Title |
|---|
| 杨靖等: "高效液相色谱法测定注射用盐酸左氧氟沙星的含量", 《赤峰学院学报(科学教育版)》 * |
| 许晓文等: "盐酸左氧氟沙星含量测定方法研究", 《中国药业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Czyrski | Analytical methods for determining third and fourth generation fluoroquinolones: A Review | |
| CN104965041A (en) | High performance liquid chromatography detection method for parecoxib sodium isomer | |
| CN109374781B (en) | Method for detecting related substances in mezlocillin sodium and sulbactam sodium for injection | |
| CN106841443A (en) | A kind of method for determining Levocarnitine Injection determined content and impurity and application thereof | |
| CN112763623B (en) | Method for detecting peramivir trihydrate by reversed-phase high-performance liquid chromatography | |
| CN112156078A (en) | Terbinafine hydrochloride tablet, preparation method thereof, impurity and quality detection method | |
| CN110286162B (en) | Method for determining dissolution rate of medicinal preparation containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate | |
| CN104771368B (en) | Cefpodoxime Proxetil quick releasing formulation and preparation method thereof | |
| CN113640416A (en) | Content determination method of levofloxacin hydrochloride tablets | |
| CN109596728B (en) | Method for measuring dissolution rate of acarbose tablets | |
| CN113063889A (en) | Method for detecting content of folic acid enantiomer | |
| CN112336693A (en) | Method for rapidly controlling and evaluating release of macitentan tablets | |
| CN1790013B (en) | A method for simultaneous determination of protocatechuic acid and 5-hydroxymethylfurfural in Shengmai injection | |
| CN107941969B (en) | The detection method of (2S,5R)-phenoxyaminopiperidine-2-carboxamide | |
| CN111707766A (en) | Detection method of furotriptan succinate tablet | |
| CN113325101B (en) | Method for detecting dissolution rates of glucosamine hydrochloride preparation in different media | |
| CN104807898A (en) | HPLC (High Performance Liquid Chromatography) method for determining dissolution rate of Lercanidipine hydrochloride tablet | |
| CN110542737B (en) | Detection method for dissolution determination of flunarizine hydrochloride capsule | |
| CN114965754A (en) | Method for detecting related substances and bacteriostatic agent in acetaminophen tablet | |
| CN115493917A (en) | A kind of dissolution curve determination method of Relugoli tablet | |
| CN111077235B (en) | Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity | |
| CN109001342B (en) | High performance liquid chromatography method for detecting N-2, 3-dimethoxybenzyl piperonylethylamine and salt content thereof | |
| CN111812227A (en) | Method for analyzing benserazide impurity A in poly-barserazide compound preparation | |
| CN115078572B (en) | A method for determination of folic acid impurities by ultra-high performance liquid chromatography | |
| CN115950999B (en) | HPLC detection method for simultaneously detecting API free base and paired organic acid in norepinephrine bitartrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211112 |